Core Viewpoint - The stock of Xinwei Medical-B (6609.HK) surged over 12%, reaching a peak of 54.05 HKD, driven by positive market sentiment regarding brain-computer interface (BCI) technology and its commercial potential in a nearly 10 billion USD market [1]. Industry Summary - The brain-computer interface sector is at a critical stage characterized by increased policy support, rapid technological advancements, and accelerated commercialization [1]. - The market for BCI technology is projected to be a nearly 10 billion USD blue ocean market, indicating significant growth opportunities [1]. Company Summary - Xinwei Medical is highlighted as a key player in the BCI space, benefiting from advancements in invasive, semi-invasive, and interventional technologies that offer unmatched advantages in signal quality and control precision [1]. - Domestic companies, including Xinwei Medical, have made technological breakthroughs in flexible electrodes and real-time Chinese language decoding, contributing to the acceleration of domestic substitution and showcasing significant long-term growth potential [1].

心玮医疗-B(6609.HK)大涨超12%，最高触及54.05港元。 消息面上，光大证券发表研报指，脑机接口作为生命科学与信息技术融合的前沿领域，现在正处于政策 支持加码、技术快速迭代、商业化加速落地的关键阶段，全球近百亿美元蓝海市场加速开启。该行指 出，侵入式、半侵入式与介入式技术在信号质量、控制精度上具备不可替代优势，是复杂应用场景的核 心解决方案，国内企业在柔性电极、汉语实时解码等领域实现技术突破，国产化替代加速，长期成长潜 力显著，建议关注心玮医疗等。 在政策端，12月18日，国家药监局在北京召开脑机接口医疗器械工作推进会。会议要求，要坚持安全有 效为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学 研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，以问题为导向，提升产 品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患者。(格隆汇) ...

Core Viewpoint - The article discusses the recent advancements and strategic importance of brain-computer interface (BCI) medical devices, highlighting the government's commitment to fostering innovation and establishing a robust industry framework by 2030 [3][4]. Group 1: Policy and Strategic Importance - The National Medical Products Administration held a meeting on December 18, 2025, to discuss the development of BCI medical devices, emphasizing the need for safety and effectiveness as primary considerations [3]. - The meeting called for enhanced collaboration across various sectors, including academia, research, and medical institutions, to address key technical challenges and improve the supply chain [3]. - The Ministry of Industry and Information Technology, along with six other departments, previously issued guidelines to promote innovation in the BCI industry, recognizing it as a frontier technology merging life sciences and information sciences [3]. Group 2: Industry Development Goals - By 2027, significant breakthroughs in BCI technology are expected, with the establishment of advanced technical, industrial, and standard systems, aiming for products to reach international standards in performance [4]. - The BCI industry is projected to expand significantly, creating 2 to 3 industrial clusters and exploring new applications and business models by 2027 [4]. - By 2030, the BCI industry aims to enhance its innovation capabilities, develop a reliable industrial ecosystem, and nurture 2 to 3 globally influential leading companies alongside a number of specialized small and medium enterprises [4].

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by recent developments in regulatory support and technological advancements [1]. Group 1: Stock Performance - Nanjing Panda (00553) increased by 4.16%, reaching HKD 4.51 [1] - MicroPort NeuroTech (02172) rose by 4.24%, trading at HKD 10.83 [1] - BrainCo (06681) saw a 2.58% increase, priced at HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for innovative regulatory methods, the establishment of standard systems, and enhanced technical guidance [1] Group 3: Industry Outlook - According to Guotai Junan, the BCI industry is poised for significant growth due to technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a promising market outlook [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a significant surge in stock prices, driven by government support and technological advancements, indicating a promising market outlook for the industry [1] Group 1: Stock Performance - Nanjing Panda (600775) shares increased by 4.16%, reaching HKD 4.51 [1] - Microwin Brain Science (02172) shares rose by 4.24%, reaching HKD 10.83 [1] - Brain Motion Aurora-B (06681) shares grew by 2.58%, reaching HKD 5.96 [1] Group 2: Regulatory Developments - The National Medical Products Administration held a meeting on December 18 to advance BCI medical device initiatives [1] - The meeting emphasized the strategic importance of BCI in future industry development and the need for safety and effectiveness as primary considerations [1] - It called for enhanced cross-departmental collaboration to address key technical challenges and improve the industry supply chain [1] Group 3: Market Outlook - According to Guotai Junan, the BCI industry is expected to benefit from technological breakthroughs, policy support, and capital investment [1] - There is an anticipated release of demand in downstream markets such as healthcare and consumer goods, indicating a positive market outlook [1]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in stock prices, driven by recent government initiatives and the potential for significant market opportunities in healthcare and consumer sectors [1] Industry Summary - The National Medical Products Administration held a meeting on December 18 to promote the development of medical devices related to brain-computer interfaces, emphasizing the strategic importance of BCIs for future industries [1] - The meeting highlighted the need for safety and effectiveness as primary considerations, along with innovative regulatory methods and the establishment of a standard system [1] - There is a call for enhanced collaboration across various sectors, including industry, academia, and healthcare, to address key technological challenges and improve the supply chain [1] - Companies are urged to take responsibility for product reliability and competitiveness, aiming to expedite the clinical application of BCI devices for patient benefit [1] Company Summary - Stocks of companies involved in the BCI sector, such as Nanjing Panda (up 4.16% to HKD 4.51), MicroPort NeuroTech (up 4.24% to HKD 10.83), and BrainCo (up 2.58% to HKD 5.96), have seen significant increases [1] - Analysts from Guotai Junan point out that the BCI industry is poised for substantial growth due to technological breakthroughs, policy support, and capital investment, indicating a promising market outlook [1]

会议要求，要深入贯彻落实党的二十届四中全会精神，深刻领会脑机接口作为前瞻布局未来产业的重要 战略意义；要坚持安全有效为首要前提，创新审评监管方法，构建标准体系，加强技术指导服务；要加 强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责 任，以问题为导向，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床、惠及患 者。 人民财讯12月19日电，12月18日，国家药监局在北京召开脑机接口医疗器械工作推进会。会议听取高等 院校、科研院所、医疗机构相关专家学者和研发企业代表意见建议。国家药监局党组成员、副局长雷平 出席会议并讲话。 ...